Visby Medical
Visby Medical develops instrument-free, single-use PCR tests for infectious diseases, including an FDA-authorized at-home women's sexual health test.
Secondary Market Price
How Visby Medical Measures Up
To help you manage your Visby Medical equity, Prospect has run the company through our machine learning model.
Prospect Rating
--
This rating reflects our belief in this company's potential to grow to that many times its current value in 4 years. For an employee with stock, this rating suggests a potential return on equity, but it also comes with some risk.
Exit Risk
--
Our rating is a reflection of the likelihood of this company achieving a liquidity event for its employees based on the quality of investors, funding stage, founders, and more.
Funding Stage
Series E
A company’s funding stage reflects how established it is, how quickly it is scaling, and the average impact an employee may have when joining.
Secondary Market Price Chart
Create a free account to unlock real-time secondary market prices and future projections of Visby Medical's value.
Sign up to Unlock the Latest DataData will be available soon.
Sign up to receive notifications when it is available.
Prospect Projected Future Visby Medical Prices
Prospect’s machine learning model has been trained on the same data top-tier investors use to project the likely range of outcomes for Visby Medical's equity. Create a free account to view 10th-90th percentile projections over 2, 4, and 6 years.
Powerful tools to earn more from your equity
Company Description
Visby Medical is a medical diagnostics company that develops instrument-free, single-use polymerase chain reaction (PCR) tests for infectious diseases. The company’s primary product is an FDA-authorized at-home test for women's sexual health, which detects chlamydia, gonorrhea, and trichomoniasis from a single swab and provides results within 30 minutes. This test is available over the counter and is supported by a digital application that connects users with telehealth providers for treatment. Visby also produces a Respiratory Health Test for influenza A, influenza B, and COVID-19, intended for use in point-of-care settings such as urgent care and campus health centers. Founded in 2012 by Adam de la Zerda, the San Jose-based company has focused on developing a technology platform to decentralize lab-quality diagnostics for consumer use.
Visby Medical's strategy involves expanding its at-home testing model to cover a broader range of conditions beyond its initial focus on women's sexual health. Recent company milestones include securing partnerships with Quest Diagnostics and Labcorp to make its Women's Sexual Health Test available on their national consumer platforms. To facilitate distribution, the company has also partnered with on-demand delivery services DoorDash and Gopuff. For its digital infrastructure, which includes result delivery and telehealth integration, Visby Medical utilizes Google Cloud. These developments have been covered by media outlets including Bloomberg and The Associated Press.
- Catalio Capital Management
- ND Capital
- Cedars Sinai Medical Center
- Blue Water Life Science Advisors
- Pitango Ventures
- John Doerr
- Ping An Voyager Partners
- Healthcare of Ontario Pension Plan
- Artiman Ventures
- Nissim Capital
- Lightrock
- J Ventures
- OMRON Ventures
- Co-Founder, Adam de la Zerda
- Co-Founder, Greg Loney
Peer Group Comparison
Vs Peer Group of >$4B Startups
Frequently Asked Questions
Joining Anduril as an employee is another way to acquire equity, typically through stock options included in compensation packages.
Is Visby Medical worth joining?
Deciding if a company is the right fit depends on personal career goals, company culture, and the specifics of the compensation package. Tools like Prospect can help you analyze the value of your equity offer and compare it to other opportunities to make a data-driven decision.
What should I do with my Visby Medical stock?
The right strategy for your Visby Medical stock depends on your personal financial situation, risk tolerance, and goals. Platforms like Prospect build customized, multi-year plans for exercising options and selling shares to help you maximize your earnings and minimize taxes.
Can you sell Visby Medical stock?
Selling stock in a private company is typically possible during specific liquidity events, such as a tender offer or through secondary markets, but it is not as simple as selling public stock. Prospect offers tools to help you navigate these sales and determine which shares are the most tax-optimal to sell.
How can I find the value of my Visby Medical stock?
Valuing stock in a private company is challenging because it isn’t traded on a public exchange. You can use a platform like Prospect, which uses machine learning models and proprietary data to project the future value of your equity.
What is Visby Medical's equity worth?
The precise worth of equity in a private company like Visby Medical is not public information and can fluctuate based on many factors. Tools like Prospect can provide a data-driven estimate by using predictive models trained on data similar to what venture capitalists use.
What is Visby Medical's stock ticker symbol?
As a private, pre-IPO company, Visby Medical does not have a stock ticker symbol. Ticker symbols are only assigned to companies once they become publicly traded on a stock exchange.
Can I buy or sell Visby Medical stock?
For employees, "buying" stock typically means exercising your stock options, while selling is usually restricted to company-approved liquidity events like tender offers or secondary sales. Financial modeling tools from Prospect can help you create an optimal strategy for both exercising and selling your shares.
What is the criteria to buy or invest in Visby Medical stock?
Investing in a private company like Visby Medical is typically limited to employees receiving equity compensation or accredited investors participating in specific funding rounds. The general public cannot purchase shares as they would with a publicly traded company.
